ArticleScience (New York, N.Y.)2023
A
Open access · greenAbstract read
In one paragraph
Article in Science (New York, N.Y.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed, 1 pooled it
20.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 1 synthesis or guideline pooled it, 106 citations in OpenAlex.
- Antifungal resistance and poor clinical outcome rates ofFrontiers in microbiology · 2026Pooled it
- Pathogenicity and virulence ofVirulence · 2026Review
- The role ofmBio · 2026Article
- Transfer ofOpen forum infectious diseases · 2026Article
- Review
- Precision nanomedicine for pulmonary diseases: from molecular targeting to clinical translation.Signal transduction and targeted therapy · 2026Review
- Baicalein suppresses adhesion and biofilm formation inMicrobiology spectrum · 2026Article
- Candida auris uses nutrient sensing to modulate virulence and host immune responses.Nature microbiology · 2026Article
- The urgent and challenging superbug fungus Candidozyma auris (formerly Candida auris): a comprehensive review.Antonie van Leeuwenhoek · 2026Review
- Innovation in antifungal therapy.EMBO molecular medicine · 2026Review
- Insights on molecular drivers of phenotypic plasticity in Candidozyma auris.World journal of microbiology & biotechnology · 2026Review
- Article
- The Wor2 phenotypic switching regulator controls biofilm formation in Candida auris.NPJ biofilms and microbiomes · 2026Article
- Heat Shock Proteins in Medically Relevant Fungal Pathogens: From Molecular Chaperones to Virulence Factors and Therapeutic Targets.Journal of fungi (Basel, Switzerland) · 2026Review
- Article
- Article
- Diabetes and Immunosuppression Drive Distinct Patterns ofbioRxiv : the preprint server for biology · 2026Article
- Defining thebioRxiv : the preprint server for biology · 2026Article
- Trk1 potassium transport is crucial for effectiveProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Functional and Biochemical Characterization of Spermidine Synthase CauSpe3 fromPathogens (Basel, Switzerland) · 2026Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
12 authors at 5 institutions in 2 countries.
Darian J SantanaDepartment of Microbiology and Immunology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-5847-8352
Juliet A E AnkuDepartment of Microbiology and Immunology, University of Michigan, Ann Arbor, MI, USA.
Guolei ZhaoDepartment of Microbiology and Immunology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0001-9605-0704
Robert ZarnowskiDepartment of Medicine, University of Wisconsin, Madison, WI, USA.ORCID 0000-0001-6343-1500
Chad J JohnsonDepartment of Medicine, University of Wisconsin, Madison, WI, USA.
Haley HautauDivision of Infectious Disease, The Lundquist Institute for Biomedical Innovation at Harbor-University of California, Los Angeles Medical Center, Torrance, CA, USA.ORCID 0000-0003-1628-0994
Noelle D VisserDepartment of Microbiology and Immunology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-9025-6020
Ashraf S IbrahimDivision of Infectious Disease, The Lundquist Institute for Biomedical Innovation at Harbor-University of California, Los Angeles Medical Center, Torrance, CA, USA.ORCID 0000-0003-3787-8530
David AndesDepartment of Medicine, University of Wisconsin, Madison, WI, USA.ORCID 0000-0002-7927-9950
Jeniel E NettDepartment of Medicine, University of Wisconsin, Madison, WI, USA.ORCID 0000-0001-8587-6244
Shakti SinghDivision of Infectious Disease, The Lundquist Institute for Biomedical Innovation at Harbor-University of California, Los Angeles Medical Center, Torrance, CA, USA.ORCID 0000-0001-6521-0998
Teresa R O'MearaDepartment of Microbiology and Immunology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-8901-0154
University of Michigan · USUniversity of Wisconsin–Madison · USUniversity of California, Los Angeles · USUCLA Medical Center · USUniversity of Ghana · GH
Funding
The Effect of Nanoparticle Encapsulated Resveratrol on Treatment of PeriodontitisKL2TR001882 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Elizabeta Nemeth · 2016 to 2026
$13.1MRESEARCH TRAINING IN EXPERIMENTAL IMMUNOPATHOLOGYT32AI007413 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Bethany B. Moore · 1993 to 2026
$9.8MVesicle-mediated drug resistance of Candida albicans biofilmR01AI073289 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI ANDES, DAVID R, MITCHELL, AARON P · 2008 to 2025
$7.9MNovel Toxins and Receptors in Mucormycosis Pathogenesis and TreatmentR01AI063503 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI IBRAHIM, ASHRAF S. · 2006 to 2025
$7.3MMolecular Mechanisms of Microbial Pathogenesis Training ProgramT32AI007528 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CARRUTHERS, VERNON BRUCE · 1998 to 2024
$6.8MCross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens SupplementR01AI141202 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI IBRAHIM, ASHRAF S. · 2019 to 2023
$5.7MMechanism(s) of pathogenicity for Candida aurisR01AI145939 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI NETT, JENIEL E · 2020 to 2025
$2.7MCharacterizing Candida auris skin colonization and high-burden biofilm formationR21AI159583 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI NETT, JENIEL E · 2021 to 2022
$427kGenetic characterization of C. auris adhesionR21AI169186 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI OMEARA, TERESA R. · 2022 to 2023
$416kMolecular Mechanisms of Candida auris Adhesion to Abiotic SurfacesF31AI169823 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SANTANA, DARIAN JAY · 2023 to 2024
$56kAmerican Heart Association-American Stroke Association 938451NCATS NIH HHS KL2 TR001882NIAID NIH HHS F31 AI169823NIAID NIH HHS R01 AI063503NIAID NIH HHS R01 AI073289NIAID NIH HHS R01 AI141202NIAID NIH HHS R01 AI145939NIAID NIH HHS R21 AI159583NIAID NIH HHS R21 AI169186NIAID NIH HHS T32 AI007413NIAID NIH HHS T32 AI007528
Abstract
PubMed holds no abstract for this paper.
Indexed as
Candida aurisCandidiasis, InvasiveFungal ProteinsMicrofilament ProteinsAnimalsHumansHydrophobic and Hydrophilic InteractionsMiceProtein DomainsVirulenceactin interacting protein 1Fungal ProteinsMicrofilament Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.